D
D&D Pharmatech
Develops GLP-1 class peptide therapeutics for metabolic diseases, including obesity, MASH, and diabetes
About D&D Pharmatech
D&D Pharmatech is a clinical-stage biopharmaceutical company specialized in GLP-1 class peptide therapeutics for metabolic diseases, including obesity, MASH, and diabetes. Its pipeline spans oral and long-acting formulations, built on its proprietary ORALINK oral peptide delivery platform and long-acting peptide technologies. The company develops programs both independently and with partners, having struck global licensing deals with Metsera, Salubris, and Blue Earth Diagnostics, and collaborating with Pfizer. Founded in 2014 in South Korea, it listed on KOSDAQ in May 2024 and runs global clinical development through its U.S.-based subsidiary Neuraly. Its pipeline also extends to fibrotic, neurodegenerative, and oncology indications, along with ventures in radiopharmaceuticals and genomic diagnostics.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Seongnam-si, South Korea
- Listing
- IPO 2024
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 71.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Radiology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2018
- Capital deployed
- $36M
- Preferred round
- SERIES A
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2025 | $0 | — | DS Asset Management · Korea Investment & Securities · Kudos Ventures · Praxis Capital Partners | ↗ |
| POST IPO CONVERTIBLEOther financing | Jun 2025 | $16M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $3.6M | 0% |
| 2025 | $3.6M | -62.4% |
| 2024 | $9.6M | -38.8% |
| 2023 | $16M | — |
Growth signals
Latest recorded traffic for D&D Pharmatech is 11K monthly website visits, up 48.6% over the last three months. D&D Pharmatech's team declined 6.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A8 investors entered at this stage
LB Investment
Magna Investment
InterVest
SmileGate Investment
Geon Investment
Dongkoo Bio&Pharma
Maryland Venture Fund- OSOctave Life Sciences
Series B and later5 investors entered at this stage
Praxis Capital Partners
DS Asset Management- KSKorea Investment & Securities
Kudos Venture Capital- KVKudos Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about D&D Pharmatech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See D&D Pharmatech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.